∙ Subjects meeting all inclusion criteria will be considered for enrollment in the study.

• Age 22 to 85 years.

• Informed consent was obtained from subject or acceptable subject surrogate (e.g., next of kin, or legal representative).

• A new focal disabling neurologic deficit consistent with acute cerebral ischemia.

• Baseline NIHSS obtained prior to procedure ≥ 6 points and ≤ 25 points.

• Pre-ictal mRS score of 0,1 or 2.

• Treatable within 16 hours of symptom onset, defined as point in time when the subject was last observed to be asymptomatic; treatment start is defined by arterial puncture time.

• If indicated, thrombolytic therapy shall be initiated per the institution's usual care and the most recent version of the AHA/ASA Guidelines. Subjects eligible for IV thrombolysis should receive it without delay.

• Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery M1 segment or, dominant or proximal M2 segment, indicated for mechanical thrombectomy, confirmed with conventional angiography or CTA/MRA.

• Imaging criteria:

‣ Perfusion weighted criterion: volume of diffusion restriction visually assessed

‣ ≤ 50 mL on CTP/MRP, or

⁃ CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 on baseline CT/DWI-MRI. (Inclusion of subjects with ASPECTS 5 is permitted at centers performing scoring on MRI)

⁃ The subject is indicated for a neurovascular thrombectomy procedure with an approved stent retriever per its Instructions for Use.